Professor Nitz states: "Our finding of significant improvements in both event-free and overall survival for high-dose chemotherapy compared with a dose-dense conventional regimen contrasts with the results of other studies...The heterogeneous [different] designs of the trials that have been conducted to date have not allowed identification of a single promising strategy. Nevertheless, the superiority of high-dose chemotherapy in our trial suggests that this strategy remains valid for further investigation."
Contact:
Professor Ulrike Nitz
University of Dusseldorf, Moorenstr
5, D 40225 Dusseldorf, Germany.
T) 49-211-811-7550
nitzu@uni-duesseldorf.de
The Lancet